FDA Approved Products
1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
DOCETAXEL
docetaxel
Peak
Viatris (2)
INJECTION · INJECTABLE
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2022
NDA0/100
DOCIVYX
docetaxel
Peak
Viatris (2)
INTRAVENOUS · SOLUTION
metastatic breast cancer after failure of prior chemotherapymetastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy+6
2022
NDA0/100
DOJOLVI
triheptanoin
Peak
Ultragenyx Pharmaceutical
ORAL · LIQUID
2020
NDA0/100
DORYX
doxycycline hyclate
Peak
ORAL · TABLET, DELAYED RELEASE
Rocky Mountain spotted fevertyphus fever+19
2005
NDA0/100
DORYX MPC
doxycycline hyclate
Peak
ORAL · TABLET, DELAYED RELEASE
Rocky Mountain spotted fevertyphus fever+19
2005
NDA0/100
DRIZALMA SPRINKLE
duloxetine
Peak
Fosun Pharma
ORAL · CAPSULE, DELAYED REL PELLETS
following conditions: • Major Depressive Disorder (MDD) in adults (1) • Generalized Anxiety Disorder (GAD) in adultsolder (1) • Diabetic Peripheral Neuropathic Pain (DPNP) in adults (1) • Fibromyalgia (FM) in adults (1) • Chronic Musculoskeletal Pain in adults (1)+1
2019
NDA0/100
DROSPIRENONE
drospirenone
Peak
Xeltis
ORAL · TABLET, CHEWABLE
pregnancy
2022
NDA0/100
DSUVIA
sufentanil
Peak
Convert Pharmaceuticals
SUBLINGUAL · TABLET
2018
NDA0/100
DUOBRII
halobetasol propionate and tazarotene
Peak
Bausch + Lomb
TOPICAL · LOTION
psoriasis
2019
NDA0/100
DURYSTA
bimatoprost
Peak
AbbVie
OPHTHALMIC · IMPLANT
intraocular pressure (IOP) in patients with open angle glaucoma (OAG)ocular hypertension (OHT)+2
2020
NDA0/100
DUZALLO
allopurinol; lesinurad
Peak
Ironwood Pharmaceuticals
ORAL · TABLET
leukemialymphoma
2017
NDA0/100
DYANAVEL XR
amphetamine
Peak
ORAL · SUSPENSION, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 yearsolder () Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure+1
2015
NDA0/100
DYANAVEL XR 10
amphetamine
Peak
ORAL · TABLET, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 yearsolder () Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure+1
2021
NDA0/100
DYANAVEL XR 15
amphetamine
Peak
ORAL · TABLET, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 yearsolder () Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure+1
2021
NDA0/100
DYANAVEL XR 20
amphetamine
Peak
ORAL · TABLET, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 yearsolder () Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure+1
2021
NDA0/100
DYANAVEL XR 5
amphetamine
Peak
ORAL · TABLET, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 yearsolder () Limitations of Use The use of DYANAVEL XR is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure+1
2021
NDA0/100
ECOZA
econazole nitrate
Peak
TOPICAL · AEROSOL, FOAM
interdigital tinea pedis caused by Trichophyton rubrumTrichophyton mentagrophytes+2
2013
NDA0/100
EDARBYCLOR
azilsartan kamedoxomil and chlorthalidone
Peak
R-Pharm US
ORAL · TABLET
hypertensionto lower blood pressure: In patients not adequately controlled with monotherapy ( )+7
2011
NDA0/100
EDLUAR
zolpidem tartrate
Peak
Viatris (2)
SUBLINGUAL · TABLET
insomnia
2009
NDA0/100
ELCYS
cysteine hydrochloride
Peak
INTRAVENOUS · SOLUTION
2019
NDA0/100
ELIGARD KIT
leuprolide acetate
Peak
Tolmar
SUBCUTANEOUS · POWDER
advanced prostate cancerprostate cancer
2004
NDA0/100
ELIGARD KIT
leuprolide acetate
Peak
Tolmar
SUBCUTANEOUS · POWDER
advanced prostate cancerprostate cancer
2002
NDA0/100
ELIGARD KIT
leuprolide acetate
Peak
Tolmar
SUBCUTANEOUS · POWDER
advanced prostate cancerprostate cancer
2002
NDA0/100
ELIGARD KIT
leuprolide acetate
Peak
Tolmar
SUBCUTANEOUS · POWDER
advanced prostate cancerprostate cancer
2003
NDA0/100